2/NIAGARA trial: Perioperative durvalumab with NAC in operable bladder cancer à EFS and OS benefit. ⏩32% reduction in risk of recurrence/death ⏩ 25% reduction in the risk of death ⏩No new safety signals. 🎯Potential new SOC for cisplatin-eligible MIBC! #ESMO2024 Plenary

I found this #AUC3 poll particularly interesting. Look to the right ... I think we struggle with the application of "adjuvant pembro" following #SBRT for M1 disease (<1 yr after initial surgery). Sounds like the jury is very split on this one ... Rana McKay, MD, FASCO Laurence Albiges

Great to have you & so many other experts in #kidneycancer & #bladdercancer here, Shilpa Gupta! It's clear from just the first session that #AUC3 is a meeting that's here to stay ... a rare opportunity to convene such a tremendous group of experts to reach consensus around

So honored to be here!! Thanks for such an amazing meeting! Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Rana McKay, MD, FASCO Jonathan Rosenberg MD

El Dr. Enrique Trilla , jefe de Urologia-Hospital Universitari Vall d’Hebron, ha sido nombrado Profesor Titular por la Universitat Autònoma de Barcelona de la UD Vall d’Hebron. ¡¡¡Enhorabuena!!!

Enhorabuena!!!👏🏻👏🏻👏🏻

Treatment free survival is becoming an important endpoint when looking at different #mRCC treatments. VEGF alone had shortest TFS. Something to be said about treatment breaks. Thx to #mehulgupta and #meredithregan IMDC Rana McKay, MD, FASCO Tom Powles Toni Choueiri, MD European Urology Oncology

Diving into the KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) & novel immunotherapy agents for advanced ccRCC! 💡🔬 New data on cutting-edge treatments for better outcomes ASCO #GU25 Cris

Durvalumab + Savolitinib in MET-driven aPRC: Strong Efficacy! -RR 59%, PFS 16.7m, OS 27.4m in MET-driven tumors. 🧬ctDNA positivity linked to worse OS 🩸🧬ctDNA clearance = better PFS Francesca Jackson-Spence, MBChB, BSc Barts and The London, Queen Mary Cris Tom Powles #GU25 @asco

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts buff.ly/4gVNIDl The COSMIC-021 study investigated the safety and efficacy of cabozantinib combined with atezolizumab in patients

STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma tandfonline.com/doi/full/10.10… The management of advanced non-clear cell renal cell carcinoma (nccRCC) is difficult due to the rarity and heterogeneity of the

Mañana 17 por la tarde dará comienzo el XI BEST GU 2024 Inspira Network Cris #BestGU donde se analizará con detalle lo mejor en #tumoresgenitourinarios de 2024. Serán dos jornadas de tarde. Puedes consultar el programa aquí 👇 bestguvirtual.com/?utm_source=IX…

LITESPARK-005 Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma #RCC sciencedirect.com/science/articl… Belzutifan, a hypoxia-inducible factor-2α (HIF-2α) inhibitor, has demonstrated improved patient-reported outcomes (PROs) in the phase 3

#Debate – Management of recurrence after curative surgery: What is the new standard of care? Surgical resection, tyrosine kinase inhibitors, immunotherapy, or radiotherapy? Presented by Petrus Järvinen, Ben Vanneste, Laurence Albiges and Cris. #EAU25 written coverage by Rashid K. Sayyid >

Long day, but proud to present our poster “Management Sequences and Clinical Outcomes in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): A real world analysis”. Grateful for the chance! #IKCSEU25 Cris

🌟Insightful, data-rich, and clinically grounded presentation by Cris at #IKCSEU25 Kidney Cancer OncoAlert 🟠 Belzutifan shows 49% ORR and 98% clinical benefit in VHL-associated RCC 🟠 Strong responses also seen in pancreatic (77%) and neuroendocrine tumors (94%) 🟠

Hablando de “Microbiome in RCC: where are we?”. Gracias por la oportunidad Cris! Seguimos sumando…

Atezolizumab plus cabozantinib or cabozantinib alone showed efficacy and manageable safety in second-line renal cell carcinoma, according to the phase 3 CONTACT-03 trial. #kcsm #ASCO25 | Cris hubs.li/Q03qshDW0

Current status of adiuvant #immunotherapy in #RCC: a Delphi study coordinated by Bernard Escudier. Full article here: doi.org/10.1016/j.ejca… #CancerResearch #oncology #genitourinary #RCC #Immunotherapy

Un orgullo haber formado parte de tan brillante panel de ponentes y moderadores en el Hot Spots de Uro-Oncologia en Barcelona, de la mano de Cris y Enrique Gallardo 👏👏👏